CRO Quality Benchmarking - Phase II/III Service Providers - WFXG FOX54 Augusta - Your News One Hour Earlier

CRO Quality Benchmarking - Phase II/III Service Providers

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Research and Markets

DUBLIN, Ireland, January 31, 2014 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/xrl265/2013_cro_quality) has announced the addition of the "CRO Quality Benchmarking - Phase II/III Service Providers" report to their offering.
     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

This study surveyed 157 pharmaceutical and biotechnology professionals about their experiences with 29 small, mid-size, and large Phase II/III CROs. In total, data were collected on 470 service encounters.

Respondents were clear in their praise of DCRI staff, labeling them as industry leaders in therapeutic expertise' and providing promising feedback across nearly all of the Staff Characteristics measured in this report, explained Kevin Olson, CEO of Industry Standard Research. However, respondents do report a narrower range of services from DCRI than others in this category.

In its 5th year, the CRO Quality Benchmarking series has been designed for the pharmaceutical industry and its service providers:

This report serves as a much needed tool and information resource to ensure that the critical Sponsor/CRO relationship is as productive as possible. By fully understanding each service provider's Staff, Organizational, and Operational strengths and weaknesses, ISR feels a sponsor can more effectively select service providers that complement its strategy and in-house resources.

In addition to showcasing CRO strengths and weaknesses, the study delivers a detailed analysis of CRO selection drivers, outsourcing volume, preferred CROs, and more. The report contains 246 pages with over 350 graphs and insightful analysis.

CROs included in this analysis: Accenture, Aptiv Solutions, Bioclinica, Charles River, Chiltern, Clinsys, Cognizant, Covance, Davita Clinical Research, DCRI-Duke, Encorium, Eurofins, ICON, INC Research, Medpace, Novella, Paragon, PAREXEL, PharmaNet / i3, PPD, PRA, Premier Research, Quintiles, Rho, RPS, SGS Life Sciences, Tata, Theorem, and Worldwide Clinical Trials.


Key Topics Covered:

Copyright and Usage Guidelines

Introduction

Outsourcing Behaviors, Attitudes, Beliefs, and Intentions

Performance Summary by Category

Summary Outcome Measures: SVI and Customer Loyalty

Company Service Quality Profiles

Study Data

Cross-service Provider Performance


Companies Mentioned:

  • Accenture
  • Aptiv Solutions
  • Bioclinica
  • Charles River
  • Chiltern
  • Clinsys
  • Cognizant
  • Covance
  • Dcri-Duke
  • Davita Clinical Research
  • Encorium
  • Eurofins
  • Icon
  • Inc Research
  • Medpace
  • Novella
  • Parexel
  • Ppd
  • Pra
  • Paragon
  • Pharmanet / I3
  • Premier Research
  • Quintiles
  • Rps
  • Rho
  • Sgs Life Sciences
  • Tata
  • Theorem
  • Worldwide Clinical Trials



For more information visit http://www.researchandmarkets.com/research/xrl265/2013_cro_quality


Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net


©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow